Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891448606> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W2891448606 abstract "10519 Background: Dexrazoxane is protective for lower-dose doxorubicin ( < 300 mg/m 2 ) cardiotoxicity in childhood cancer, but the effect of dexrazoxane (DXRZ) administered with higher-dose (HD) doxorubicin (DOXO) is unknown. Methods: We evaluated patients from Children’s Oncology Group trials for localized (P9754) and metastatic (AOST0121) osteosarcoma (OS) who received HD DOXO (375-600 mg/m 2 ) preceded by DXRZ (10:1 ratio), methotrexate, and cisplatin; some also received ifosfamide alone or ifosfamide/etoposide ± trastuzumab. Cardiotoxicity was identified by echocardiography and by serum N-terminal pro-brain natriuretic peptide (NT-proBNP) concentrations. Results: 81 DXRZ -treated OS patients ( age at enrollment = 13.7 years; range 3.8 - 23.7 years) had normal left ventricular (LV) systolic function as measured by LV fractional shortening and no heart failure. Female sex and longer follow-up since DOXO were associated with a significantly smaller LV dimension z-score normalized to BSA (μ = -1.20, 95%CI [-1.70, -0.70]). Similarly, in the one-third of patients treated > 81 days after minimal expected treatment (groups equally partitioned by time), significantly thinner LV posterior wall thickness for BSA (μ = -0.57, [-1.05, -0.09]) was found. Interventricular septal wall thickness (μ = -0.84, [-1.2, -0.48]) and LV mass (μ = -0.73, [-1.06, -0.40]) were significantly smaller for BSA than normal for both sexes. For females, these became significantly more abnormal with increasing length of follow-up. Females also showed progressive increases in NT-proBNP. Conclusions: DXRZ is cardioprotective for HD DOXO in terms of LV function and heart failure. Females had progressive abnormalities of LV structure, leading to smaller hearts for body size. This was associated with increasing cardiac stress, as measured by NT-proBNP. DXRZ protection was incomplete for HD DOXO effects on LV structure, resulting in higher LV stress and risk for late LV dysfunction. DXRZ should continue to be used in this population, including for females who exhibit more cardiotoxicity than males at specific cumulative DOXO doses." @default.
- W2891448606 created "2018-09-27" @default.
- W2891448606 creator A5010913859 @default.
- W2891448606 creator A5011956202 @default.
- W2891448606 creator A5013088250 @default.
- W2891448606 creator A5025395169 @default.
- W2891448606 creator A5027865998 @default.
- W2891448606 creator A5032743242 @default.
- W2891448606 creator A5042223616 @default.
- W2891448606 creator A5043820682 @default.
- W2891448606 creator A5056053037 @default.
- W2891448606 creator A5067299217 @default.
- W2891448606 creator A5072502431 @default.
- W2891448606 creator A5080725919 @default.
- W2891448606 creator A5081072468 @default.
- W2891448606 creator A5082899595 @default.
- W2891448606 creator A5085873078 @default.
- W2891448606 creator A5090325707 @default.
- W2891448606 date "2017-05-20" @default.
- W2891448606 modified "2023-09-27" @default.
- W2891448606 title "Complete dexrazoxane cardioprotection for cardiac function but incomplete female cardioprotection for cardiac structure in doxorubicin-treated osteosarcoma survivors: Hearts too small for the body." @default.
- W2891448606 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.10519" @default.
- W2891448606 hasPublicationYear "2017" @default.
- W2891448606 type Work @default.
- W2891448606 sameAs 2891448606 @default.
- W2891448606 citedByCount "0" @default.
- W2891448606 crossrefType "journal-article" @default.
- W2891448606 hasAuthorship W2891448606A5010913859 @default.
- W2891448606 hasAuthorship W2891448606A5011956202 @default.
- W2891448606 hasAuthorship W2891448606A5013088250 @default.
- W2891448606 hasAuthorship W2891448606A5025395169 @default.
- W2891448606 hasAuthorship W2891448606A5027865998 @default.
- W2891448606 hasAuthorship W2891448606A5032743242 @default.
- W2891448606 hasAuthorship W2891448606A5042223616 @default.
- W2891448606 hasAuthorship W2891448606A5043820682 @default.
- W2891448606 hasAuthorship W2891448606A5056053037 @default.
- W2891448606 hasAuthorship W2891448606A5067299217 @default.
- W2891448606 hasAuthorship W2891448606A5072502431 @default.
- W2891448606 hasAuthorship W2891448606A5080725919 @default.
- W2891448606 hasAuthorship W2891448606A5081072468 @default.
- W2891448606 hasAuthorship W2891448606A5082899595 @default.
- W2891448606 hasAuthorship W2891448606A5085873078 @default.
- W2891448606 hasAuthorship W2891448606A5090325707 @default.
- W2891448606 hasConcept C111566952 @default.
- W2891448606 hasConcept C121608353 @default.
- W2891448606 hasConcept C126322002 @default.
- W2891448606 hasConcept C164705383 @default.
- W2891448606 hasConcept C2776694085 @default.
- W2891448606 hasConcept C2776802502 @default.
- W2891448606 hasConcept C2777760704 @default.
- W2891448606 hasConcept C2778198053 @default.
- W2891448606 hasConcept C2778233292 @default.
- W2891448606 hasConcept C2779676291 @default.
- W2891448606 hasConcept C2779720357 @default.
- W2891448606 hasConcept C2781303535 @default.
- W2891448606 hasConcept C500558357 @default.
- W2891448606 hasConcept C502942594 @default.
- W2891448606 hasConcept C530470458 @default.
- W2891448606 hasConcept C71924100 @default.
- W2891448606 hasConceptScore W2891448606C111566952 @default.
- W2891448606 hasConceptScore W2891448606C121608353 @default.
- W2891448606 hasConceptScore W2891448606C126322002 @default.
- W2891448606 hasConceptScore W2891448606C164705383 @default.
- W2891448606 hasConceptScore W2891448606C2776694085 @default.
- W2891448606 hasConceptScore W2891448606C2776802502 @default.
- W2891448606 hasConceptScore W2891448606C2777760704 @default.
- W2891448606 hasConceptScore W2891448606C2778198053 @default.
- W2891448606 hasConceptScore W2891448606C2778233292 @default.
- W2891448606 hasConceptScore W2891448606C2779676291 @default.
- W2891448606 hasConceptScore W2891448606C2779720357 @default.
- W2891448606 hasConceptScore W2891448606C2781303535 @default.
- W2891448606 hasConceptScore W2891448606C500558357 @default.
- W2891448606 hasConceptScore W2891448606C502942594 @default.
- W2891448606 hasConceptScore W2891448606C530470458 @default.
- W2891448606 hasConceptScore W2891448606C71924100 @default.
- W2891448606 hasLocation W28914486061 @default.
- W2891448606 hasOpenAccess W2891448606 @default.
- W2891448606 hasPrimaryLocation W28914486061 @default.
- W2891448606 hasRelatedWork W157257041 @default.
- W2891448606 hasRelatedWork W1990423255 @default.
- W2891448606 hasRelatedWork W1997046585 @default.
- W2891448606 hasRelatedWork W2009766464 @default.
- W2891448606 hasRelatedWork W2075648840 @default.
- W2891448606 hasRelatedWork W2115021514 @default.
- W2891448606 hasRelatedWork W2589276516 @default.
- W2891448606 hasRelatedWork W2607643254 @default.
- W2891448606 hasRelatedWork W2889216848 @default.
- W2891448606 hasRelatedWork W2950355863 @default.
- W2891448606 hasRelatedWork W2964320615 @default.
- W2891448606 hasRelatedWork W3011400996 @default.
- W2891448606 hasRelatedWork W3012010769 @default.
- W2891448606 hasRelatedWork W3037672008 @default.
- W2891448606 hasRelatedWork W3047969638 @default.
- W2891448606 hasRelatedWork W3157789342 @default.
- W2891448606 hasRelatedWork W3159419788 @default.
- W2891448606 hasRelatedWork W2460898798 @default.
- W2891448606 isParatext "false" @default.
- W2891448606 isRetracted "false" @default.
- W2891448606 magId "2891448606" @default.
- W2891448606 workType "article" @default.